START FREE TRIAL
Home Healthcare Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

$19.00

SKU: REGN Category:

Description

Regeneron Pharmaceuticals’ $7 Billion Sanofi Opportunity: A New Growth Catalyst?

 

Regeneron Pharmaceuticals, Inc. reported a 36% increase in total revenues to $5.1 billion in the third quarter of 2026 compared to the same period in 2025. This growth was primarily driven by strong commercial performance across key products and an expanded collaboration agreement with Sanofi, which contributed $1.0 billion in upfront payments expected to be recognized in the fourth quarter alongside potential milestone payments up to $7.0 billion. Key products Dupixent, EYLEA HD, and Libtayo each achieved record global or U.S. net sales increases of 35%, 62%, and 51%, respectively. GAAP earnings per share rose 35% to $18.45, while non-GAAP EPS increased 70% to $20.07, reflecting improved profitability alongside sales growth. Collaboration revenue from Sanofi rose significantly by 68% due to higher profits from antibody commercialization and the full repayment of the Sanofi Development Balance, eliminating prior revenue offsets.